New drug cocktail aims to tackle tough lymphoma in vulnerable patients

NCT ID NCT06357676

Recruiting now Disease control Sponsor: OHSU Knight Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of three drugs—glofitamab, ibrutinib, and obinutuzumab—in people with mantle cell lymphoma who are either 65 or older, or between 18 and 64 with high-risk features. The goal is to see if the combo is safe and can shrink or eliminate tumors. Participants will receive the drugs intravenously and by mouth, along with regular scans and blood tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: glofitamab, ibrutinib, and obinutuzumab
What this could lead to: If successful, this combination could offer a new, more effective treatment option for mantle cell lymphoma, especially for older or high-risk patients.
What could go wrong: This is an early-phase trial with only 27 participants, so results may not apply broadly. Side effects like cytokine release syndrome or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

OHSU Knight Cancer Institute
RECRUITING

Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.